RE: Exclusivity1 Oct 2018 21:24
bidnolid...try reading the RNS's - No ramping required here
The collaboration has begun well and the Nuvec® team (the "Team") is making significant progress developing manufacturing methods for Nuvec® particles loaded with therapeutic DNA/RNA encoding protein antigens. Once completed, MedImmune will then conduct studies to demonstrate the capability of delivering such antigens to induce immune responses, the results of which are expected in Q4 2018.
Â
Additional Research and Development pipeline
Â
In addition to the immune response work referred to above, further research will be carried out this year to identify in which human cells Nuvec® nanoparticles are most effective for transfection, as well as characterising dose and duration of response at the site of injection, including rate of breakdown and distribution in the body. In addition, further work will be performed to optimise manufacture of Nuvec® nanoparticles and understand their stability in various media, which will be informative regarding formulation considerations.
Â
The Company expects all of these results, along with our internal immune response work, to be available in Q4 2018 which, together with the MedImmune collaboration results, will be used to form the strategy for prioritising the development of therapeutic uses of the Nuvec® platform over the next year